In coronary artery occlusion study, Droxicainide reduces hypoperfused area that evolves to necrosis, and reduces the infarct size in dogs. Droxicainide decreases the sinus node, atrial and ventricular excitability and contractile force and increases the refractoriness in the study of spontaneously beating atria, electrically stimulated atria and papillary muscles isolated from rats.